What is the share price of Jeena Sikho Lifecare Ltd (JSLL) today?
The share price of JSLL as on 2nd March 2026 is ₹606.15. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Jeena Sikho Lifecare Ltd (JSLL) share?
The past returns of Jeena Sikho Lifecare Ltd (JSLL) share are- Past 1 week: -11.67%
- Past 1 month: -8.58%
- Past 3 months: -15.09%
- Past 6 months: -14.01%
- Past 1 year: 97.98%
- Past 3 years: 1958.93%
- Past 5 years: 3047.20%
What are the peers or stocks similar to Jeena Sikho Lifecare Ltd (JSLL)?
The peers or stocks similar to Jeena Sikho Lifecare Ltd (JSLL) include:What is the dividend yield % of Jeena Sikho Lifecare Ltd (JSLL) share?
The current dividend yield of Jeena Sikho Lifecare Ltd (JSLL) is 0.18.What is the market cap of Jeena Sikho Lifecare Ltd (JSLL) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Jeena Sikho Lifecare Ltd (JSLL) is ₹7534.49 Cr as of 2nd March 2026.What is the 52 week high and low of Jeena Sikho Lifecare Ltd (JSLL) share?
The 52-week high of Jeena Sikho Lifecare Ltd (JSLL) is ₹849.50 and the 52-week low is ₹294.20.What is the PE and PB ratio of Jeena Sikho Lifecare Ltd (JSLL) stock?
The P/E (price-to-earnings) ratio of Jeena Sikho Lifecare Ltd (JSLL) is 83.04. The P/B (price-to-book) ratio is 27.60.Which sector does Jeena Sikho Lifecare Ltd (JSLL) belong to?
Jeena Sikho Lifecare Ltd (JSLL) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Jeena Sikho Lifecare Ltd (JSLL) shares?
You can directly buy Jeena Sikho Lifecare Ltd (JSLL) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Jeena Sikho Lifecare Ltd
JSLL Share Price
NSE₹606.150.41% (-2.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
JSLL Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
HighStrong financials and growth story over the years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
JSLL Performance & Key Metrics
JSLL Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 37.30 | 27.60 | 0.18% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.67 | 5.79 | 0.58% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
JSLL Company Profile
Jeena Sikho Lifecare is engaged in developing health care products and providing ayurvedic healthcare services in India.
SUNPHARMA
PE Ratio
38.47
38.47
1Y Return
10.56%
10.56%
Buy Reco %
94.29
94.29
TORNTPHARM
PE Ratio
77.37
77.37
1Y Return
47.65%
47.65%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
20.71
20.71
1Y Return
3.97%
3.97%
Buy Reco %
54.84
54.84
DRREDDY
PE Ratio
19.06
19.06
1Y Return
15.61%
15.61%
Buy Reco %
48.39
48.39
LUPIN
PE Ratio
32.19
32.19
1Y Return
18.34%
18.34%
Buy Reco %
72.22
72.22
JSLL Sentiment Analysis
JSLL Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
JSLL Stock Summary · February 2026
The company has demonstrated remarkable financial growth, with a 400% increase in profit after tax and a 240% rise in EBITDA, driven by higher patient numbers and innovative Ayurvedic product offerings. Strategic international expansion into markets like the UAE and Kazakhstan, coupled with a focus on enhancing operational capacity, positions the company for sustained profitability. While challenges persist, such as cyclicality in healthcare demand and a shift away from low-margin government contracts, management remains optimistic about leveraging health insurance reimbursements and expanding its OTC product distribution. The commitment to quality, evidenced by extensive research and community engagement initiatives, further strengthens its market position in the evolving wellness landscape.
JSLL Stock Growth Drivers
JSLL Stock Growth Drivers
7Strong Financial Performance
The company reported significant financial growth, with total operational income reaching INR 221.7 crores, a
Operational Growth and Patient Engagement
The company experienced substantial operational growth, with outpatient and video consultations increasing by 247%, inpatient
JSLL Stock Challenges
JSLL Stock Challenges
4Declining Government Business
The company has experienced a significant reduction in government business, with revenue from this sector
Occupancy and Capacity Challenges
The company reported an occupancy rate of only 58% in the current quarter, which is
JSLL Forecast
JSLL Forecasts
Price
Revenue
Earnings
JSLL Share Price Forecast
JSLL Share Price Forecast
2026
Current
₹606.15
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
2026
Current
₹606.15
Baseline
Forecast for Mar 2027
High
₹—
Median
₹—
Low
₹—
All values in ₹
JSLL Company Revenue Forecast
JSLL Company Revenue Forecast
2025
Current
₹475.48
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
2025
Current
₹475.48
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ cr.
JSLL Stock EPS (Earnings Per Share) Forecast
JSLL Stock EPS (Earnings Per Share) Forecast
2025
Current
₹7.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹7.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
JSLL
JSLL
Income
Balance Sheet
Cash Flow
Quarterly Normal View
JSLL Income Statement
JSLL Income Statement
Quarterly Normal View
| Quarter | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 102.67 | 117.54 | 116.08 | 139.52 | 175.35 | 191.29 | 224.25 | |||||||
Operating & Other expenses | 75.09 | 73.82 | 86.08 | 93.48 | 95.53 | 97.82 | 120.96 | |||||||
EBITDA | 27.58 | 43.72 | 30.00 | 46.04 | 79.82 | 93.47 | 103.29 | |||||||
| Depreciation/Amortization | 5.36 | 6.25 | 8.47 | 9.03 | 9.65 | 10.40 | 11.26 | |||||||
| PBIT | 22.22 | 37.47 | 21.53 | 37.01 | 70.17 | 83.07 | 92.03 | |||||||
| Interest & Other Items | 1.70 | 2.07 | 3.79 | 3.10 | 1.66 | 4.35 | 3.10 | |||||||
| PBT | 20.52 | 35.40 | 17.74 | 33.91 | 68.51 | 78.72 | 88.93 | |||||||
| Taxes & Other Items | 4.79 | 8.81 | 4.53 | 8.58 | 17.24 | 19.97 | 22.27 | |||||||
| Net Income | 15.73 | 26.59 | 13.21 | 25.33 | 51.27 | 58.75 | 66.66 | |||||||
| EPS | 0.25 | 0.43 | 0.21 | 0.41 | 4.12 | 4.73 | 5.36 |
JSLL Company Updates
JSLL Stock Peers
JSLL Past Performance & Peer Comparison
JSLL Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Jeena Sikho Lifecare Ltd | 83.04 | 27.60 | 0.18% |
| Sun Pharmaceutical Industries Ltd | 38.47 | 5.80 | 0.91% |
| Torrent Pharmaceuticals Ltd | 77.37 | 19.48 | 0.73% |
| Cipla Ltd | 20.71 | 3.49 | 1.18% |
JSLL Stock Price Comparison
Compare JSLL with any stock or ETFCompare JSLL with any stock or ETF
JSLL
JSLL Holdings
JSLL Shareholdings
JSLL Promoter Holdings Trend
JSLL Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
JSLL Institutional Holdings Trend
JSLL Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
JSLL Shareholding Pattern
JSLL Shareholding Pattern
JSLL Shareholding History
JSLL Shareholding History
Foreign Institutions
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing JSLL stock
smallcases containing JSLL stock
Looks like this stock is not in any smallcase yet.
JSLL Events
JSLL Events
JSLL Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
JSLL Dividend Trend
No dividend trend available
JSLL Upcoming Dividends
JSLL Upcoming Dividends
No upcoming dividends are available
JSLL Past Dividends
JSLL Past Dividends
Cash Dividend
Ex DateEx DateSep 22, 2025
Final
Final | Div/Share: ₹1.10
Dividend/Share
₹1.10
Ex DateEx Date
Sep 22, 2025
Cash Dividend
Ex DateEx DateAug 20, 2024
Final
Final | Div/Share: ₹4.18
Dividend/Share
₹4.18
Ex DateEx Date
Aug 20, 2024
Cash Dividend
Ex DateEx DateAug 25, 2023
Final
Final | Div/Share: ₹2.00
Dividend/Share
₹2.00
Ex DateEx Date
Aug 25, 2023
JSLL Stock News & Opinions
JSLL Stock News & Opinions
Articles & Videos
Corporate
Jeena Sikho Lifecare receives NABH accreditation for Dehradun Hospital
Jeena Sikho Lifecare has been awarded the National Accreditation Board for Hospitals & Healthcare Providers (NABH) Certificate of Accreditation for its Dehradun Hospital. The receipt of this NABH accreditation signifies adherence to nationally recognized standards for quality healthcare delivery, patient safety, and operational excellence. This development has occurred in the ordinary course of business and does not constitute business expansion, capacity enhancement, or acquisition.Powered by Capital Market - Live
1 week agoCapital Market - Live
Earnings
Jeena Sikho Lifecare standalone net profit rises 405.15% in the December 2025 quarter
Net profit of Jeena Sikho Lifecare rose 405.15% to Rs 66.73 crore in the quarter ended December 2025 as against Rs 13.21 crore during the previous quarter ended December 2024. Sales rose 91.60% to Rs 221.66 crore in the quarter ended December 2025 as against Rs 115.69 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales221.66115.69 92 OPM %45.4825.59 - PBDT100.2726.21 283 PBT89.0617.74 402 NP66.7313.21 405 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Jeena Sikho Lifecare announces board meeting date
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 7 February 2026.Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Earnings
Jeena Sikho Lifecare standalone net profit rises 121.02% in the September 2025 quarter
Net profit of Jeena Sikho Lifecare rose 121.02% to Rs 58.79 crore in the quarter ended September 2025 as against Rs 26.60 crore during the previous quarter ended September 2024. Sales rose 66.40% to Rs 189.85 crore in the quarter ended September 2025 as against Rs 114.09 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales189.85114.09 66 OPM %48.5035.31 - PBDT89.1641.66 114 PBT78.7635.41 122 NP58.7926.60 121 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare to discuss results
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare commences operations of 230-bed hospital in Maharashtra
Jeena Sikho Lifecare has commenced operations of its 230-bed hospital at Raigad District, Maharashtra with effect from 23 September 2025.Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare conducts clinical trials for four products
Jeena Sikho Lifecare has received approval for conducting a clinical trial on the following products: 1. Anti-Diabetes Efficacy of SDM02 Tablets - Pre-clinical study conducted at MIET, Meerut, on streptozotocin-induced diabetic rats. The tablets were found effective with no mortality or adverse effects at the tested dose. 2. Shuddhi XS Syrup - Clinical trial on 60 subjects with constipation conducted at CCFT Laboratories, Meerut. 92% reported relief in constipation and abdominal pain, with no adverse events. 3. Petshuddhi Churna - Retrospective clinical study on 100 patient records conducted at Hospital & Institute of Integrated Medical Sciences, Meerut. Significant improvement observed in bowel movement, stool consistency, and abdominal discomfort. No adverse events reported. 4. Shuddhi Dr. B P Care Tablets - Clinical trial on 60 hypertensive patients conducted at CCFT Laboratories, Meerut. Significant reduction in systolic and diastolic blood pressure and heart rate was observed within 2-3 hours and sustained for 6 hours. No adverse events reported. Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare AGM scheduled
Jeena Sikho Lifecare announced that the Annual General Meeting(AGM) of the company will be held on 29 September 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Jeena Sikho Lifecare announces board meeting date
Jeena Sikho Lifecare will hold a meeting of the Board of Directors of the Company on 27 August 2025.Powered by Capital Market - Live
6 months agoCapital Market - Live
Earnings
Jeena Sikho Lifecare standalone net profit rises 217.91% in the June 2025 quarter
Net profit of Jeena Sikho Lifecare rose 217.91% to Rs 51.31 crore in the quarter ended June 2025 as against Rs 16.14 crore during the previous quarter ended June 2024. Sales rose 74.22% to Rs 174.29 crore in the quarter ended June 2025 as against Rs 100.04 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales174.29100.04 74 OPM %45.2124.64 - PBDT78.2026.35 197 PBT68.5521.07 225 NP51.3116.14 218 Powered by Capital Market - Live
6 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 37.95%, vs industry avg of 9.88%
Over the last 5 years, market share increased from 0.04% to 0.11%
Over the last 5 years, net income has grown at a yearly rate of 73.69%, vs industry avg of 19.69%